Exelixis Highlights Oncology Innovations at December Investor Conferences

Exelixis Showcases Commitment to Oncology at Upcoming Investor Conferences

Exelixis, Inc., an innovative oncology company based in Alameda, California, is gearing up for significant presentations at two notable investor conferences in early December 2023. This strategic participation underscores Exelixis’s commitment to advancing cancer care through its cutting-edge therapies and research initiatives. On December 3rd, the company will present at the Piper Sandler 36th Annual Healthcare Conference in New York City, followed by a session at the Citi 2024 Global Healthcare Conference in Miami on December 4th. Both events aim to highlight Exelixis’s ongoing efforts in drug discovery and development, particularly in the oncology space.

At these conferences, Exelixis plans to showcase its diverse portfolio, which includes its flagship product, CABOMETYX® (cabozantinib). CABOMETYX has proven to be a transformative treatment for various tumor types and indications, reflecting Exelixis’s dedication to improving the quality of life for cancer patients. The company employs a multifaceted approach to oncology, focusing on small molecules, antibody-drug conjugates, and other biotherapeutics, which positions it uniquely in the competitive landscape of cancer treatment. By leveraging decades of research and strategic partnerships, Exelixis is poised to expand its impact on cancer care and reach more patients in need.

Exelixis’s participation in these conferences is part of its broader strategy to engage with investors and stakeholders, fostering transparency and collaboration within the healthcare community. The company encourages interested parties to access the live webcasts of the presentations through its website, ensuring that the latest advancements and insights in oncology are readily available. With replays accessible for at least 30 days, Exelixis demonstrates its commitment not only to innovation in cancer treatment but also to maintaining an open dialogue with the investment community.

In addition to its conference presentations, Exelixis continues to enhance its pipeline and extend the reach of investigational programs. With a focus on scientific excellence, the company is dedicated to creating impactful treatments that offer hope to cancer patients. For more information about Exelixis and its mission in oncology, stakeholders can visit the company’s website or engage with its content on various social media platforms.